TITE-gBOIN-ET: time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes

DOI10.1002/BIMJ.202200265MaRDI QIDQ6572287zbMATHFDO

Authors Kentaro Takeda, Yusuke Yamaguchi, Masataka Taguri, Satoshi Morita

Publication date 15 July 2024

Published in Biometrical Journal (Search for Journal in Brave)

zbMATH Keywords

model-assisted designBayesian adaptive dose-finding designphase I-II clinical trial designefficacy and toxicity gradelate-onset outcome

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• scientific article; zbMATH DE number 3390139 (Why is no real title available?)
• scientific article; zbMATH DE number 2242805 (Why is no real title available?)
• A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
• Bayesian designs for phase I--II clinical trials
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
• TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials

This page was built for publication: TITE-gBOIN-ET: time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6572287)